Long-term toxicity of immune suppression in juvenile rheumatic diseases.
Although there are not many studies which have addressed long-term outcomes in children with rheumatic disease treated with immunosuppressive agents, the data that are available, as well as information from adult studies, suggest significant long-term concerns with all the agents that have demonstrable efficacy. This must lead us to investigate new methods of treatment which will not only be more effective, but also less toxic.
Laxer
R M
RM
Department of Paediatrics and Medicine, University of Toronto and the Hospital for Sick Children, Ontario, Canada.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000477:Alkylating Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D002648:Child; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D012216:Rheumatic Diseases / Q000628:therapy*; D013995:Time
D000305:Adrenal Cortex Hormones; D000477:Alkylating Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D008727:Methotrexate